Loading stock data…
BioNTech SE (BNTX)
$94.26+3.04 (+3.33%)
Market ClosedLast close Jun 29
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioNTech SE in the Healthcare sector is trading at $94.26 with a market capitalization of $22.8B. Wall Street consensus targets $121.78 (20 analysts), implying a +29.2% move over the next 12 months. The stock is currently 24% below its 52-week high of $124.00, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 75 is overbought against a weak tape. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +29.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 75 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $118.10M↓ | $907.40M↓ | $1.52B↑ | $260.80M↑ | $182.80M |
| Gross Profit | $46.70M↓ | $574.10M↓ | $1.37B↑ | $184.40M↑ | $99.00M |
| Operating Income | -$671.20M↓ | -$280.50M↓ | $653.90M↑ | -$478.50M↑ | -$561.50M |
| Net Income | -$531.90M↓ | -$305.00M↓ | -$28.70M↑ | -$386.60M↑ | -$415.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.70%
Volume
Today's trading volume
919,424
Recent News
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
US Equity Markets End Lower After Government Bond Yields Rise, Fed's Policy Statement
US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve ann
Sector Update: Healthcare Stocks Retreat Late Afternoon
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were sharply higher late Wednesda